Effect of L-carnitine and conjugated linoleic acid supplements on haemoglobin levels and haptoglobin genotype in chronic kidney disease by نعمتی, علی et al.
Introduction 
Chronic kidney disease (CKD) is a worldwide public health 
threat which is a cause of considerable increase in 
cardiovascular morbidity and premature mortality. The 
prevalence of CKD stages 3-5 in Iran is 14.9%.1 Anaemia is 
a common complication of CKD2 which may be due to 
lack of erythropoietin, low folic acid, vitamin B12 and iron 
levels.3 It has been shown that correction of anaemia is 
associated with improved outcomes in CKD patients.4 In 
patients with CKD, anaemia can be treated using 
recombinant human erythropoietin, but some of these 
patients develop resistance to erythropoietin.5 In CKD, 
chronic inflammation plays an important role in the 
disease process.6 It has been reported that the resistance 
to erythropoietin treatment is one of the important 
outcomes of chronic inflammation in CKD.7 Several 
proteins such as haptoglobin (HP) are produced from 
hepatocytes during chronic inflammation in CKD. HP 
binds to haemoglobin (Hb) to prevent renal clearance of 
Hb and renal damage caused by free Hb.8 HP-Hb complex 
modulate inflammation by the inhibition of prostaglandin 
synthesis.9 HP is encoded by 2 distinct alleles of HP1 and 
HP2, and these two alleles produce 3 phenotypes: HP1-1, 
HP1-2 and HP2-2.10 The frequency of HP alleles varies 
among different populations. In addition, HP levels may 
be dependent on HP phenotype, so that those with the 
HP1-1 phenotype have the highest HP serum 
concentrations.11 
HP participates in Hb and iron metabolism. It may affect 
anaemia and Hb levels by controlling the inflammation 
process. It has been shown that different HP phenotypes 
can cause various responses in the host against 
inflammation.12,13 The antioxidant effects of nutrient 
supplement such as conjugated linoleic acid (CLA) and L-
carnitine (LC) have been investigated separately in 
CKD.14,15 CKD patients undergoing haemodialysis usually 
suffer from LC deficiency.16 LC has an inhibitory property 
on inflammatory markers, lipid peroxidation and 
apoptosis pathways.17 Furthermore, LC supplements may 
increase haematocrit (HCT) levels and decrease 
erythropoietin requirement.18,19 
CLA is another diet supplement that is important in 
human nutrition due to its health benefits such as being 
anti-inflammatory, anti-obesity, anti-cancer, anti-
atherosclerosis and anti-diabetic.20 A number of studies 
showed that CLA prevents the secretion of inflammatory 
cytokines and modulates the host inflammatory 
response.21 
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Abstract 
Objective: To investigate the efficacy of L-carnitine (LC) and conjugated linoleic acid (CLA) supplements on 
haemoglobin levels and inflammatory markers in chronic kidney disease (CKD) patients with different haptoglobin 
(HP) genotypes. 
Methods: This clinical trial study was conducted at Imam Khomeini Hospital, Ardabil, and Labbafinejad Hospital, 
Tehran, Iran, from March 2014 to March 2015, and comprised male patients with CKD and anaemia. Anthropometric 
factors were recorded and demographic data was collected using general questionnaires. LC (1 g/day) and CLA (2.4 
g/day) supplements were given to the patients for a month. Blood samples were taken to measure haematological 
and inflammatory markers at the beginning and end of the study. Haptoglobin genotypes were determined using 
polymerase chain reaction (PCR). SPSS 21 was used for data analysis. 
Results: Among the 40 patients in the study, HP2-2 genotype was the most prevalent genotype (62.5%). The level 
of haemoglobin was significantly increased in the patients at the end of the study (p< 0.05). No significant changes 
were found in the weight, body mass index and serum levels of Interleukin-6, high-sensitivity C-reactive protein, 
ferritin, total iron-binding capacity and iron (p>0.05 each). 
Conclusion: Regular diet supplementation with LC plus CLA can improve haemoglobin levels in CKD patients with 
anaemia. 
Keywords: Haptoglobin genotype, CKD, Anaemia, CLA, L-carnitine. (JPMA 69: 343; 2019)
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The current study was planned to evaluate the efficacy of 
CLA and LC combination on Hb level and inflammatory 
factors in CKD patients with different haptoglobin 
genotype. 
Materials and Methods  
This clinical trial study was conducted at Imam Khomeini 
Hospital, Ardabil, and Labbafinejad Hospital, Tehran, Iran, 
from March 2014 to March 2015. During one-year period 
of time, based on inclusion criteria, we selected 50 CKD 
patients with anaemia referring to these two centres. Ten 
participants of them were excluded due to non-
cooperation and abuse of supplements. Finally, 40 male 
CKD patients with anaemia from 18-60 years old were 
recruited. CKD was defined as glomerular filtration rate 
(GFR) = 15-90 mL/min and anaemia was defined as Hb less 
than 13g/dl. 
The sample size was determined according to the 
formula:22 
N = [(Zα+Zβ)/C]2 + 3, C = 0.5 * ln[(1+r)/(1-r)] 
In the formula, N= total sample size, C= expected 
correlation coefficient, Zα= the probability of committing 
a type I error, Zβ= the probability of committing a type II 
error, r= the correlation coefficient, ln = natural logarithm. 
CKD patients suffering from other chronic diseases such 
as cardiovascular diseases, thyroid disease, malignancies, 
diabetes and those who took iron supplements were 
excluded. 
The study was approved by the research ethics 
committee of Ardabil University of Medical Sciences 
(Ethical code: Arums.REC.93.65) and recorded in the 
Iranian Registry of Clinical Trials identification code of 
IRCT201503055144N7. Written informed consent was also 
obtained from each participant before the initiation of the 
study. After getting the consent, general information, 
anthropometric factors (height and weight) and fasting 
blood samples, both supplements of LC (1gm per day) 
and CLA (2.4 gm per day) were given to subjects by oral 
administration for one month. The possible risks and 
complications of the pills were explained to the 
patients.23 The patients were called every week for follow-
up and it was ensured that the participants had 
consumed the supplements. The patients' compliance 
with the consumption of the pills was evaluated by the 
remaining pills at the end of the 4th week. The patient's 
weight and height were recorded and their body mass 
index (BMI) was calculated and categorised as per defined 
standards.24 The individuals' fasting weights were 
measured with an accuracy of 0.5 kg. Each time at certain 
stages, accuracy and precision of the Seca scales were 
calibrated using a standard 5kg weight. In the beginning 
and at the end of the study, after 10-12 hours of overnight 
fasting, 5ml venous blood sample was taken from all 
patients. The Hb and HCT were measured using cell 
counter. Serum was separated from the whole blood and 
kept frozen at -80°C until experimental analysis. The 
serum levels of iron and total iron-binding capacity (TIBC) 
were measured using the photometric method. Serum 
levels of Interleukin 6 (IL-6) were measured by enzyme-
linked immunosorbent assay (ELISA), according to the 
manufacturer's instructions (ZellBio GmbH, Ulm, 
Germany). 
Genomic deoxyribonucleic acid (DNA) was extracted from 
peripheral blood leukocytes using CinnaPure® DNA 
extraction Kit (SinaClon, Tehran, Iran). The primers A (5’-
GAGGGGAGCTTGCCTTTCCATTG-3’) and B (5’-
GAGATTTTTGAGCCCTGGCTGGT-3’) were used for 
amplification of the 1757-bp and 3481-bp for HP1 and 
HP2 allele-specific sequences, respectively. The primers C 
(5’-CCTGCCTCGTATTAACTGCACCAT-3’) and D (5’-
CCGAGTGCTCCACATAGCCATGT-3’) were used to amplify 
a 349-bp HP2 allele-specific sequence.25 Hp genotypes 
were determined by polymerase chain reaction (PCR) 
using 20μL total volume reactions containing 2 U/μL of 
Taq polymerase, 1-100 ng of DNA, and 200μM 
deoxyribonucleotide triphosphatess (dNTPs) mix; PCR 
buffer was used as suggested by the supplier (Fermentas 
Co, Canada). After initial denaturation at 95°C for 5 min, 
the two-step thermo cycling procedure consisted of 
denaturation at 94°C for 45 second and annealing at 62°C 
for 1 min (in the presence of primers A, B, C, and D), and 
extension at 72°C for 1 min, repeated for 35 cycles, and 
followed by a final extension at 72°C for 7 min. The 
thermocycler instrument used was Veriti 96 well (Applied 
Biosystems, USA). The PCR products for determining HP 
genotype were separated on 1% agarose gel.  
Data was analysed using SPSS 21. Kolmogorov-Smirnov 
test was performed to verify normal distribution of 
sampling. Paired sample t-test and Chi square test were 
used to determine relationship between the variables. 
Results 
Among the 40 patients analysed, genotypic frequencies 
for HP1-2 and HP2-2 genotypes were 37.5% (n=15) and 
62.5% (n=25), respectively. Of the total, 15 (37.5%) 
subjects were illiterate, 11 (27.5%) had studied up to 
primary level, and 7 (17.5%) each had secondary and 
college education (Table-1). The values of weight and BMI 
(body mass index) in patients were reduced at the end of 
study, but these differences were not significant (p>0.05). 
Hb levels were significantly increased at the end of the 
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study (p=0.001). No significant changes were observed in 
the serum levels of IL-6, hs-CRP, ferritin, TIBC, and iron 
after intervention (Table-2). Although low levels of Hb 
were seen in subjects with HP1-2 genotype, there was no 
significant association between Hb level and HP 
genotype (p=0.26). The serum levels of IL-6 and hs-CRP in 
HP2-2 genotype were slightly lower compared to HP1-2 
genotype (Table-3). Gel electrophoresis for determining 
HP genotype is presented in Figure 1. 
Discussion 
Anaemia is one of the main problems in CKD patients and 
occurs especially in the final stages of the disease. 
Although many attempts have been made to advance the 
treatment of anaemia in CKD patients, most studies 
indicate that Hb is low in these patients.7,26,27 For the first 
time, our results showed that supplementation with LC 
plus CLA significantly increased Hb levels in CKD patients. 
Very few studies have been carried out to assess the 
effects of CLA on anaemia. However, inconsistent with our 
study, a study has shown that CLA can produce acute 
oxidative damage and degrade red blood cells.28 
Regarding LC supplementation on CKD, several studies 
have been shown that it may benefit for CKD 
patients.15,29-31 Hurot et al. showed that LC 
supplementation can increase Hb and HCT levels and 
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Table-1: Haptoglobin genotype, stages of chronic kidney disease (CKD) and 
demographic factors in study subjects. 
 
Variables                                                  Condition                           No.                      Percent 
 
Haptoglobin (HP) genotype                      HP1-2                                 15                            37.5 
                                                                            HP2-2                                 25                            62.5 
Stages of CKD                                                 Stage2                                 2                                5 
                                                                           Stage3                                19                            47.5 
                                                                           Stage4                                19                            47.5 
Level of literacy                                           illiterate                               15                            37.5 
                                                                          primary                               11                            27.5 
                                                                        Secondary                              7                             17.5 
                                                                        Collegiate                              7                             17.5 
Background of renal disease                        yes                                    12                              30 
                                                                               no                                    28                              70 
Smoking history                                               yes                                    25                            62.5 
                                                                               no                                    15                            37.5 
History of alcohol use                                     yes                                     0                                0 
                                                                               no                                    40                            100 
Person's job                                                  Working                               13                            32.5 
                                                                        Employee                             11                            27.5 
                                                                           Farmer                                 7                             17.5 
                                                                   Self-employed                          9                             22.5 
 
No.= Number.
Table-2: The levels of haematological and biochemical factors in patients during study. 
 
Variables                                     Mean±SD                                   Mean±SD               P value  
                                      (At the beginning of study)     (At the end of study) 
 
IL-6 (ng/ml)                                 5.51 ± 5.71                               12.33 ± 27.68                0.13 
hs-CRP (mg/L)                            9.63 ± 10.48                               8.17 ± 19.77                 0.65 
Haemoglobin (g/dl)                   11.38 ± 1.1                                  12.05 ± 1.2                0.001* 
Ferritin (ng/ml)                      268.24 ± 295.64                         220.8 ± 254.38               0.17 
TIBC (mg/dl)                             356.12 ± 67.99                          359.55 ± 82.66               0.77 
Fe (mg/dl)                                  72.59 ± 45.12                              76.8 ± 22.85                 0.57 
 
*. Significant vs. the beginning of study (p<0.05) 
SD: Standard deviation 
hs-CRP: High-sensitivity C-reactive protein 
TIBC: Total iron-binding capacity. Fe: Iron.
Table-3: The levels of haematological and biochemical factors in patients based on 
type of haptoglobin (HP) genotypes. 
 
Variables                                    Mean±SD                                Mean±SD                   P value  
                                            (In HP1-2 genotype)          (In HP2-2 genotype) 
 
IL-6 (ng/ml)                                6.75 ± 6.28                                4.76 ± 5.34                      0.29 
hs-CRP (mg/L)                          10.5 ± 11.94                               9.1 ± 9.37                        0.69 
Haemoglobin (g/dl)                  11.1 ± 1.1                                 11.5 ± 1.06                      0.26 
Ferritin (ng/ml)                       258.5 ± 315.1                        274.09 ± 289.87                 0.87 
TIBC (mg/dl)                           349.93 ± 56.33                        359.84 ± 74.98                   0.66 
Fe (mg/dl)                                       60 ± 23                                 80.72 ± 53.22                    0.16 
 
SD: Standard deviation 
hs-CRP: high-sensitivity C-reactive protein 
TIBC: Total Iron Binding Capacity 
Fe: Iron.
Lane 1: HP1-2 genotype: amplified fragment with 3481 bp length for HP2 allele and 1757 bp 
length fragment for HP1 allele 
Lane 2: HP2-2 genotype: amplified fragment with 349 bp length for HP2 allele 
Lane 3: 100 bp DNA ladder 
 
Figure 1: Gel electrophoresis for determining haptoglobin (HP) genotype by 
polymerase chain reaction (PCR).
decrease erythropoietin requirement in haemodialysis 
patients.18 Unlike, Emami et al. showed that LC 
supplementation can decrease erythropoietin 
requirement in haemodialysis patients but it does not 
effect haemoglobin levels in these patients.32 Another 
study has shown that LC supplementation can prolong 
red blood cell (RBC) lifespan and can stimulate 
erythropoiesis by increasing the number of erythroid 
colonies.33 In addition, antioxidant and antiapoptotic 
effects of LC have also been described both in vitro and in 
vivo, as well as, it has been shown that LC 
supplementation can increase heme oxygenase-1 (HO-1) 
expression and improve erythropoiesis.29,34 Thus, 
regarding the effects of LC and CLA supplementation on 
haemoglobin levels and erythropoiesis in previous 
studies, results of our study revealed that LC plus CLA 
supplementation may be more effective in increasing 
haemoglobin levels than alone LC or CLA 
supplementation.     
Besides, a common complication in patients with CKD is 
inflammation. Serum inflammatory markers such as CRP 
are higher in CKD patients than healthy individuals. 
Inflammation can increase anaemia, cardiovascular 
diseases, malnutrition and cancer.3,35 It has been shown 
that inflammatory cytokine response through release of 
cytokines such as IL-6 and tumour necrosis factor-alpha 
(TNFα), stimulate the synthesis and release of CRP.36 In 
this study, oral LC plus CLA supplementation had no 
effect on serum levels of inflammatory markers including 
hs-CRP, IL-6 and ferritin in CKD patients. Similarly, 
Dehghan et al. showed that the serum levels of CRP didn't 
change by oral LC supplementation in haemodialysis 
patients.29 In contrast to the present study, Duranay et al. 
reported that carnitine supplementation decreased CRP 
levels and improved the chronic inflammation in 
haemodialysis patients.31 Considering the effect of CLA 
on inflammation in human population a few studies have 
been investigated. Similar to our results in the present 
study, Raff et al. demonstrated that CLA supplementation 
(5.5 g/d) did not affect inflammatory markers in healthy 
young men.37 Unlike our study, Steck et al. showed that 
CLA supplementation for 12 weeks increased 
inflammation markers including CRP in obese humans.38 
Also, LaRosa et al. indicated that CLA supplementation 
associated with increasing in inflammation response in 
rats.39 In another clinical trial, Mohammadzadeh et al. 
confirmed that CLA supplementation reduced 
inflammatory factors including hs-CRP and IL-6 in rectal 
cancer patients undergoing chemoradiotherapy.40 
Despite the fact that CLA and LC supplementation may 
have been benefit or harmful effects on inflammatory 
response, in our study CLA plus LC supplementation did 
not effect on inflammatory response in CKD patients and 
it cannot be use for inflammation controlling in these 
patients.   
Another of our interesting finding was HP2-2 genotype as 
more frequent genotype among patients with CKD 
(62.5%). In agreement with our results, Armaly et al. 
showed that HP2-2 genotype was the prevalent genotype 
(73%) in CKD patients. Moreover, their results indicated 
significant association between HP2-2 genotype and CKD. 
Also, another study has reported the association between 
HP polymorphism and CKD.41 It has been shown that the 
HP2-2 genotype is the prevalent genotype in variety of 
common disorders including cancer, renal failure and 
cardiovascular disease.8,10,22 There are several reasons to 
explain the high frequency of the HP2-2 genotype 
including high levels of oxidative stress and low serum 
levels of haptoglobin in this genotype.42,43 In addition, in 
our study, there was no relationship between HP 
genotype with inflammatory markers. The lack of 
association between inflammatory markers and HP 
genotype has not been demonstrated in previous 
studies.44,45 Recently, Mohieldein et al. found no 
significant association between HP genotype and markers 
of inflammation in diabetes.46 Thus, according to the 
present study, it may indicate that there is no connection 
between inflammatory markers and HP genotype, which 
requires further investigation.  
The level of literacy and health literacy plays an important 
role in the care of CKD.47 In our study, most people with 
renal disease were illiterate. Our results are consistent 
with the findings of Taheri et al., which showed that 
illiteracy is higher in some kidney disease such as 
haemodialysis patients.48 Knowledge and education level 
have a significant impact on the diagnosis and treatment 
of CKD. Findings of Green et al. showed that level of 
education is directly associated with better health 
outcomes in patients with kidney disease.49 Therefore, 
educating people to recognise the risk factors and healthy 
eating plays an important role in preventing kidney 
disease. 
The current study has some limitations. The sample size 
was relatively small. Other limitations included follow-up 
of patients to take medications during treatment. 
Conclusion 
This study showed for the first time that supplementation 
with LC plus CLA was effective in increasing haemoglobin 
(Hb) levels in CKD patients with anaemia. LC plus CLA 
supplementation had no effect on BMI and serum levels 
of IL-6, hs-CRP, TIBC and ferritin. 
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